BR112019023322B1 - Uso do sanfetrinem, sanfetrinem sódico ou sanfetrinem cilexetila para a produção de um medicamento para o tratamento de tuberculose e combinação de sanfetrinem - Google Patents
Uso do sanfetrinem, sanfetrinem sódico ou sanfetrinem cilexetila para a produção de um medicamento para o tratamento de tuberculose e combinação de sanfetrinem Download PDFInfo
- Publication number
- BR112019023322B1 BR112019023322B1 BR112019023322-9A BR112019023322A BR112019023322B1 BR 112019023322 B1 BR112019023322 B1 BR 112019023322B1 BR 112019023322 A BR112019023322 A BR 112019023322A BR 112019023322 B1 BR112019023322 B1 BR 112019023322B1
- Authority
- BR
- Brazil
- Prior art keywords
- mycobacterium
- sanfetrinem
- tuberculosis
- pharmaceutically acceptable
- hydroxyethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D463/12—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached in position 7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382255.2 | 2017-05-08 | ||
| EP17382255 | 2017-05-08 | ||
| PCT/EP2018/061615 WO2018206466A1 (en) | 2017-05-08 | 2018-05-04 | Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112019023322A2 BR112019023322A2 (pt) | 2020-06-16 |
| BR112019023322B1 true BR112019023322B1 (pt) | 2023-11-14 |
Family
ID=58709903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023322-9A BR112019023322B1 (pt) | 2017-05-08 | 2018-05-04 | Uso do sanfetrinem, sanfetrinem sódico ou sanfetrinem cilexetila para a produção de um medicamento para o tratamento de tuberculose e combinação de sanfetrinem |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11253500B2 (enExample) |
| EP (1) | EP3621609B1 (enExample) |
| JP (1) | JP7123074B2 (enExample) |
| KR (1) | KR102575872B1 (enExample) |
| CN (1) | CN110869016B (enExample) |
| AU (1) | AU2018265192B2 (enExample) |
| BR (1) | BR112019023322B1 (enExample) |
| CA (1) | CA3060396A1 (enExample) |
| CY (1) | CY1125546T1 (enExample) |
| DK (1) | DK3621609T3 (enExample) |
| ES (1) | ES2925215T3 (enExample) |
| HR (1) | HRP20221212T1 (enExample) |
| HU (1) | HUE059818T2 (enExample) |
| LT (1) | LT3621609T (enExample) |
| PL (1) | PL3621609T3 (enExample) |
| PT (1) | PT3621609T (enExample) |
| RS (1) | RS63461B1 (enExample) |
| RU (1) | RU2757272C2 (enExample) |
| SI (1) | SI3621609T1 (enExample) |
| SM (1) | SMT202200400T1 (enExample) |
| WO (1) | WO2018206466A1 (enExample) |
| ZA (1) | ZA201906810B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111184718A (zh) * | 2018-11-15 | 2020-05-22 | 鲁南制药集团股份有限公司 | 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途 |
| CA3206024A1 (en) * | 2021-02-01 | 2022-08-04 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid amorphous form |
| CN117462551B (zh) * | 2023-12-27 | 2024-05-17 | 深圳国家感染性疾病临床医学研究中心 | 茚地那韦和/或其衍生物在制备抗结核药物中的应用 |
| CN122124048B (zh) * | 2026-05-06 | 2026-07-24 | 深圳国家感染性疾病临床医学研究中心 | 埃替拉韦在制备结核分枝杆菌或非结核分枝杆菌的抑制剂中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ435990A3 (cs) | 1989-09-08 | 1999-11-17 | Glaxo S.P.A. | Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem |
| CA2067741C (en) | 1990-08-21 | 2002-01-01 | Alcide Perboni | 10(1-hydroxyethly)-11-oxo-1-azatricyclo[7.2.0.0.3.8]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof |
| GB9018330D0 (en) | 1990-08-21 | 1990-10-03 | Glaxo Spa | Heterocyclic compounds |
| GB9104769D0 (en) | 1991-03-07 | 1991-04-17 | Glaxo Spa | Heterocyclic compounds |
| GB9305813D0 (en) | 1993-03-20 | 1993-05-05 | Glaxo Spa | Chemical process |
| EP2085084A1 (en) * | 2008-01-29 | 2009-08-05 | LEK Pharmaceuticals D.D. | Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics |
| EP2135871A1 (en) | 2008-06-18 | 2009-12-23 | LEK Pharmaceuticals D.D. | New trinem antibiotics and inhibitors of beta-lactamases |
| WO2016046845A1 (en) | 2014-09-25 | 2016-03-31 | Manu Chaudhary | Stealth, targeted nanoparticles (stn) for oral drug delivery |
| MA41495A (fr) | 2015-02-12 | 2017-12-19 | Anacor Pharmaceuticals Inc | Composés benzoxaborole et leurs utilisations |
-
2018
- 2018-05-04 DK DK18721053.9T patent/DK3621609T3/da active
- 2018-05-04 AU AU2018265192A patent/AU2018265192B2/en active Active
- 2018-05-04 HU HUE18721053A patent/HUE059818T2/hu unknown
- 2018-05-04 SI SI201830762T patent/SI3621609T1/sl unknown
- 2018-05-04 ES ES18721053T patent/ES2925215T3/es active Active
- 2018-05-04 HR HRP20221212TT patent/HRP20221212T1/hr unknown
- 2018-05-04 CA CA3060396A patent/CA3060396A1/en active Pending
- 2018-05-04 US US16/611,908 patent/US11253500B2/en active Active
- 2018-05-04 WO PCT/EP2018/061615 patent/WO2018206466A1/en not_active Ceased
- 2018-05-04 LT LTEPPCT/EP2018/061615T patent/LT3621609T/lt unknown
- 2018-05-04 PT PT187210539T patent/PT3621609T/pt unknown
- 2018-05-04 CN CN201880030277.5A patent/CN110869016B/zh active Active
- 2018-05-04 KR KR1020197032729A patent/KR102575872B1/ko active Active
- 2018-05-04 BR BR112019023322-9A patent/BR112019023322B1/pt active IP Right Grant
- 2018-05-04 PL PL18721053.9T patent/PL3621609T3/pl unknown
- 2018-05-04 JP JP2019561315A patent/JP7123074B2/ja active Active
- 2018-05-04 EP EP18721053.9A patent/EP3621609B1/en active Active
- 2018-05-04 RU RU2019139864A patent/RU2757272C2/ru active
- 2018-05-04 SM SM20220400T patent/SMT202200400T1/it unknown
- 2018-05-04 RS RS20220731A patent/RS63461B1/sr unknown
-
2019
- 2019-10-16 ZA ZA2019/06810A patent/ZA201906810B/en unknown
-
2022
- 2022-09-13 CY CY20221100607T patent/CY1125546T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3621609B1 (en) | 2022-07-27 |
| KR20200003816A (ko) | 2020-01-10 |
| KR102575872B1 (ko) | 2023-09-08 |
| JP7123074B2 (ja) | 2022-08-22 |
| WO2018206466A1 (en) | 2018-11-15 |
| JP2020519592A (ja) | 2020-07-02 |
| RS63461B1 (sr) | 2022-08-31 |
| HRP20221212T1 (hr) | 2022-12-09 |
| DK3621609T3 (da) | 2022-08-29 |
| EP3621609A1 (en) | 2020-03-18 |
| ZA201906810B (en) | 2021-03-31 |
| BR112019023322A2 (pt) | 2020-06-16 |
| ES2925215T3 (es) | 2022-10-14 |
| SMT202200400T1 (it) | 2022-11-18 |
| LT3621609T (lt) | 2022-10-10 |
| RU2019139864A3 (enExample) | 2021-06-28 |
| SI3621609T1 (sl) | 2022-10-28 |
| CY1125546T1 (el) | 2026-02-25 |
| US11253500B2 (en) | 2022-02-22 |
| AU2018265192B2 (en) | 2021-06-17 |
| RU2757272C2 (ru) | 2021-10-12 |
| CN110869016B (zh) | 2023-09-12 |
| HUE059818T2 (hu) | 2022-12-28 |
| CN110869016A (zh) | 2020-03-06 |
| RU2019139864A (ru) | 2021-06-09 |
| PT3621609T (pt) | 2022-08-24 |
| AU2018265192A1 (en) | 2019-11-07 |
| PL3621609T3 (pl) | 2022-11-14 |
| CA3060396A1 (en) | 2018-11-15 |
| US20200289462A1 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bailo et al. | Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development | |
| US10653679B2 (en) | Compositions and methods for inhibiting bacterial growth | |
| Donald et al. | Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis | |
| JP7123074B2 (ja) | マイコバクテリア感染の処置において使用するためのサンフェトリネム、その塩、またはそのエステル | |
| Moir et al. | New classes of antibiotics | |
| CN117045657A (zh) | 一种药物组合及其应用 | |
| Salina et al. | New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis | |
| Sano et al. | Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium | |
| CN108883114B (zh) | 抗结核药物 | |
| BRPI0616659A2 (pt) | droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose | |
| JP2020519592A5 (enExample) | ||
| WO2019004466A1 (ja) | 医薬 | |
| Cheepsattayakorn et al. | Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis | |
| WO2018019031A1 (en) | A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof | |
| CN120379693A (zh) | 一种药物组合及应用 | |
| WO2024175768A1 (en) | Combination of fabi inhibitor and antibiotic agent | |
| US20220184071A1 (en) | Gepotidacin for use in the treatment of bacterial urinary tract infections | |
| Phillips et al. | Research Article Antimycobacterial Activities of Novel 5-(1H-1, 2, 3-Triazolyl) Methyl Oxazolidinones | |
| BR112018069487B1 (pt) | Usos terapêuticos de 6-((4-(2,3-dimetilfenóxi)piperidin-1- il)metil) pirimidina-2,4(1h,3h)-diona ou de um sal farmaceuticamente aceitável da mesma, combinação e composição farmacêutica que compreendem a mesma | |
| Adamovich | Anti-Tuberculosis Drug Discovery by Bioluminescence-Based Screening of a Protein Kinase Inhibitor Library Honors Research Thesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2018, OBSERVADAS AS CONDICOES LEGAIS |
|
| B25G | Requested change of headquarter approved |
Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) |